BACKGROUND: Improved vaccination strategies against tuberculosis are needed, such as approaches to boost immunity induced by the current vaccine, BCG. Design of these strategies has been hampered by a lack of knowledge of the kinetics of the human host response induced by neonatal BCG vaccination. Furthermore, the functional and phenotypic attributes of BCG-induced long-lived memory T-cell responses remain unclear. METHODS: We assessed the longitudinal CD4 T-cell response following BCG vaccination of human newborns. The kinetics, function, and phenotype of these cells were measured using flow cytometric whole-blood assays. RESULTS: We showed that the BCG-specific CD4 T-cell response peaked 6-10 weeks after vaccination and gradually waned over the first year of life. Highly activated T-helper 1 cells, predominantly expressing interferon γ, tumor necrosis factor α, and/or interleukin 2, were present at the peak response. Following contraction, BCG-specific CD4 T cells expressed high levels of Bcl-2 and displayed a predominant CD45RACCR7 central memory phenotype. However, cytokine and cytotoxic marker expression by these cells was more characteristic of effector memory cells. CONCLUSIONS: Our findings suggest that boosting of BCG-primed CD4 T cells with heterologous tuberculosis vaccines may be best after 14 weeks of age, once an established memory response has developed.
BACKGROUND: Improved vaccination strategies against tuberculosis are needed, such as approaches to boost immunity induced by the current vaccine, BCG. Design of these strategies has been hampered by a lack of knowledge of the kinetics of the human host response induced by neonatal BCG vaccination. Furthermore, the functional and phenotypic attributes of BCG-induced long-lived memory T-cell responses remain unclear. METHODS: We assessed the longitudinal CD4 T-cell response following BCG vaccination of human newborns. The kinetics, function, and phenotype of these cells were measured using flow cytometric whole-blood assays. RESULTS: We showed that the BCG-specific CD4 T-cell response peaked 6-10 weeks after vaccination and gradually waned over the first year of life. Highly activated T-helper 1 cells, predominantly expressing interferon γ, tumornecrosis factor α, and/or interleukin 2, were present at the peak response. Following contraction, BCG-specific CD4 T cells expressed high levels of Bcl-2 and displayed a predominant CD45RACCR7 central memory phenotype. However, cytokine and cytotoxic marker expression by these cells was more characteristic of effector memory cells. CONCLUSIONS: Our findings suggest that boosting of BCG-primed CD4 T cells with heterologous tuberculosis vaccines may be best after 14 weeks of age, once an established memory response has developed.
Authors: Thomas J Scriba; Michele Tameris; Nazma Mansoor; Erica Smit; Linda van der Merwe; Katya Mauff; E Jane Hughes; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Humphrey Mulenga; Marwou de Kock; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Hendrik Geldenhuys; Adrian V S Hill; Gregory D Hussey; Hassan Mahomed; Willem A Hanekom; Helen McShane Journal: J Infect Dis Date: 2011-06-15 Impact factor: 5.226
Authors: Willem A Hanekom; Jane Hughes; Maushumi Mavinkurve; Megan Mendillo; Marcia Watkins; Hoyam Gamieldien; Sebastian J Gelderbloem; Mzwandile Sidibana; Nazma Mansoor; Virginia Davids; Rose Ann Murray; Anthony Hawkridge; Patrick A J Haslett; Stanley Ress; Gregory D Hussey; Gilla Kaplan Journal: J Immunol Methods Date: 2004-08 Impact factor: 2.303
Authors: Naomi E Aronson; Mathuram Santosham; George W Comstock; Robin S Howard; Lawrence H Moulton; Everett R Rhoades; Lee H Harrison Journal: JAMA Date: 2004-05-05 Impact factor: 56.272
Authors: Martin O C Ota; Aderonke A Odutola; Patrick K Owiafe; Simon Donkor; Olumuyiwa A Owolabi; Nathaniel J Brittain; Nicola Williams; Sarah Rowland-Jones; Adrian V S Hill; Richard A Adegbola; Helen McShane Journal: Sci Transl Med Date: 2011-06-22 Impact factor: 17.956
Authors: Mark Hatherill; Thomas J Scriba; Sara Suliman; Hennie Geldenhuys; John L Johnson; Jane E Hughes; Erica Smit; Melissa Murphy; Asma Toefy; Lesedi Lerumo; Christiaan Hopley; Bernadette Pienaar; Phalkun Chheng; Elisa Nemes; Daniel F Hoft; Willem A Hanekom; W Henry Boom Journal: J Immunol Date: 2016-07-13 Impact factor: 5.422
Authors: Mardi C Boer; Corine Prins; Krista E van Meijgaarden; Jaap T van Dissel; Tom H M Ottenhoff; Simone A Joosten Journal: Clin Vaccine Immunol Date: 2015-05-06
Authors: Christophe Toukam Tchakoute; Anneke C Hesseling; Elvis B Kidzeru; Hoyam Gamieldien; Jo-Ann S Passmore; Christine E Jones; Clive M Gray; Donald L Sodora; Heather B Jaspan Journal: J Infect Dis Date: 2014-08-08 Impact factor: 5.226
Authors: Tony W Ng; Ariel S Wirchnianski; Anna Z Wec; J Maximilian Fels; Christopher T Johndrow; Kevin O Saunders; Hua-Xin Liao; John Chan; William R Jacobs; Kartik Chandran; Steven A Porcelli Journal: J Immunol Date: 2020-06-08 Impact factor: 5.422